nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—thyroid cancer—Graves' disease	0.722	1	CtDrD
Doxorubicin—CYP2B6—Methimazole—Graves' disease	0.0717	0.559	CbGbCtD
Doxorubicin—CYP2D6—Methimazole—Graves' disease	0.0346	0.27	CbGbCtD
Doxorubicin—CYP3A4—Methimazole—Graves' disease	0.022	0.172	CbGbCtD
Doxorubicin—Pigmentation disorder—Methimazole—Graves' disease	0.00521	0.0815	CcSEcCtD
Doxorubicin—DHCR7—Vitamin D Metabolism—GC—Graves' disease	0.00512	0.256	CbGpPWpGaD
Doxorubicin—Pigmentation disorder—Propylthiouracil—Graves' disease	0.00443	0.0693	CcSEcCtD
Doxorubicin—Erythema nodosum—Propylthiouracil—Graves' disease	0.00342	0.0535	CcSEcCtD
Doxorubicin—Neuritis—Methimazole—Graves' disease	0.00233	0.0364	CcSEcCtD
Doxorubicin—Ageusia—Methimazole—Graves' disease	0.00215	0.0336	CcSEcCtD
Doxorubicin—Neuritis—Propylthiouracil—Graves' disease	0.00198	0.031	CcSEcCtD
Doxorubicin—Skin ulcer—Propylthiouracil—Graves' disease	0.0019	0.0297	CcSEcCtD
Doxorubicin—Ageusia—Propylthiouracil—Graves' disease	0.00183	0.0285	CcSEcCtD
Doxorubicin—AKR1A1—eye—Graves' disease	0.00177	0.0269	CbGeAlD
Doxorubicin—ABCB8—pituitary gland—Graves' disease	0.00177	0.0269	CbGeAlD
Doxorubicin—ABCB8—adipose tissue—Graves' disease	0.00176	0.0268	CbGeAlD
Doxorubicin—Liver injury—Propylthiouracil—Graves' disease	0.00176	0.0275	CcSEcCtD
Doxorubicin—CBR3—adipose tissue—Graves' disease	0.0017	0.0258	CbGeAlD
Doxorubicin—Aplastic anaemia—Methimazole—Graves' disease	0.00163	0.0255	CcSEcCtD
Doxorubicin—NDUFS7—connective tissue—Graves' disease	0.00155	0.0236	CbGeAlD
Doxorubicin—ABCB8—thyroid gland—Graves' disease	0.00152	0.0232	CbGeAlD
Doxorubicin—Lymphadenopathy—Methimazole—Graves' disease	0.00148	0.0231	CcSEcCtD
Doxorubicin—CBR3—thyroid gland—Graves' disease	0.00147	0.0223	CbGeAlD
Doxorubicin—Aplastic anaemia—Propylthiouracil—Graves' disease	0.00139	0.0217	CcSEcCtD
Doxorubicin—NOS1—eye—Graves' disease	0.00134	0.0204	CbGeAlD
Doxorubicin—NDUFS2—eye—Graves' disease	0.00133	0.0203	CbGeAlD
Doxorubicin—AKR1A1—pituitary gland—Graves' disease	0.00131	0.02	CbGeAlD
Doxorubicin—AKR1A1—adipose tissue—Graves' disease	0.00131	0.0199	CbGeAlD
Doxorubicin—NDUFS2—connective tissue—Graves' disease	0.00129	0.0195	CbGeAlD
Doxorubicin—NDUFS3—connective tissue—Graves' disease	0.00127	0.0193	CbGeAlD
Doxorubicin—Lymphadenopathy—Propylthiouracil—Graves' disease	0.00126	0.0197	CcSEcCtD
Doxorubicin—ABCC6—eye—Graves' disease	0.00122	0.0185	CbGeAlD
Doxorubicin—Hepatic failure—Propylthiouracil—Graves' disease	0.00119	0.0187	CcSEcCtD
Doxorubicin—NDUFS7—adipose tissue—Graves' disease	0.00119	0.0181	CbGeAlD
Doxorubicin—ABCC6—connective tissue—Graves' disease	0.00118	0.0179	CbGeAlD
Doxorubicin—Renal failure acute—Propylthiouracil—Graves' disease	0.00116	0.0182	CcSEcCtD
Doxorubicin—YWHAG—eye—Graves' disease	0.00115	0.0175	CbGeAlD
Doxorubicin—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.00114	0.0178	CcSEcCtD
Doxorubicin—AKR1A1—thyroid gland—Graves' disease	0.00113	0.0172	CbGeAlD
Doxorubicin—AURKA—pituitary gland—Graves' disease	0.00111	0.0169	CbGeAlD
Doxorubicin—YWHAG—connective tissue—Graves' disease	0.00111	0.0168	CbGeAlD
Doxorubicin—RALBP1—eye—Graves' disease	0.00104	0.0158	CbGeAlD
Doxorubicin—NDUFS7—thyroid gland—Graves' disease	0.00103	0.0157	CbGeAlD
Doxorubicin—NDUFS2—pituitary gland—Graves' disease	0.00099	0.0151	CbGeAlD
Doxorubicin—NDUFS2—adipose tissue—Graves' disease	0.000986	0.015	CbGeAlD
Doxorubicin—NOS3—connective tissue—Graves' disease	0.000983	0.0149	CbGeAlD
Doxorubicin—NDUFS3—pituitary gland—Graves' disease	0.000978	0.0149	CbGeAlD
Doxorubicin—NDUFS3—adipose tissue—Graves' disease	0.000974	0.0148	CbGeAlD
Doxorubicin—Drowsiness—Methimazole—Graves' disease	0.000973	0.0152	CcSEcCtD
Doxorubicin—CBR1—eye—Graves' disease	0.000968	0.0147	CbGeAlD
Doxorubicin—AURKA—thyroid gland—Graves' disease	0.000958	0.0146	CbGeAlD
Doxorubicin—Neuropathy peripheral—Methimazole—Graves' disease	0.000954	0.0149	CcSEcCtD
Doxorubicin—Jaundice—Methimazole—Graves' disease	0.000949	0.0148	CcSEcCtD
Doxorubicin—DHCR7—pituitary gland—Graves' disease	0.000929	0.0141	CbGeAlD
Doxorubicin—DHCR7—adipose tissue—Graves' disease	0.000925	0.0141	CbGeAlD
Doxorubicin—Agranulocytosis—Methimazole—Graves' disease	0.000908	0.0142	CcSEcCtD
Doxorubicin—ABCC6—adipose tissue—Graves' disease	0.000902	0.0137	CbGeAlD
Doxorubicin—Hepatitis—Methimazole—Graves' disease	0.000874	0.0137	CcSEcCtD
Doxorubicin—NOS1—thyroid gland—Graves' disease	0.000859	0.0131	CbGeAlD
Doxorubicin—NDUFS2—thyroid gland—Graves' disease	0.000854	0.013	CbGeAlD
Doxorubicin—YWHAG—pituitary gland—Graves' disease	0.000853	0.013	CbGeAlD
Doxorubicin—YWHAG—adipose tissue—Graves' disease	0.000849	0.0129	CbGeAlD
Doxorubicin—NDUFS3—thyroid gland—Graves' disease	0.000843	0.0128	CbGeAlD
Doxorubicin—Drowsiness—Propylthiouracil—Graves' disease	0.000828	0.0129	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.000811	0.0127	CcSEcCtD
Doxorubicin—Jaundice—Propylthiouracil—Graves' disease	0.000807	0.0126	CcSEcCtD
Doxorubicin—DHCR7—thyroid gland—Graves' disease	0.000801	0.0122	CbGeAlD
Doxorubicin—ABCC6—thyroid gland—Graves' disease	0.000781	0.0119	CbGeAlD
Doxorubicin—NQO1—eye—Graves' disease	0.000776	0.0118	CbGeAlD
Doxorubicin—Agranulocytosis—Propylthiouracil—Graves' disease	0.000772	0.0121	CcSEcCtD
Doxorubicin—Alopecia—Methimazole—Graves' disease	0.000772	0.0121	CcSEcCtD
Doxorubicin—RALBP1—pituitary gland—Graves' disease	0.00077	0.0117	CbGeAlD
Doxorubicin—RALBP1—adipose tissue—Graves' disease	0.000767	0.0117	CbGeAlD
Doxorubicin—NQO1—connective tissue—Graves' disease	0.000748	0.0114	CbGeAlD
Doxorubicin—Haemoglobin—Propylthiouracil—Graves' disease	0.000747	0.0117	CcSEcCtD
Doxorubicin—Haemorrhage—Propylthiouracil—Graves' disease	0.000743	0.0116	CcSEcCtD
Doxorubicin—Hepatitis—Propylthiouracil—Graves' disease	0.000743	0.0116	CcSEcCtD
Doxorubicin—YWHAG—thyroid gland—Graves' disease	0.000735	0.0112	CbGeAlD
Doxorubicin—CBR1—pituitary gland—Graves' disease	0.000719	0.0109	CbGeAlD
Doxorubicin—CBR1—adipose tissue—Graves' disease	0.000716	0.0109	CbGeAlD
Doxorubicin—AKR1C3—pituitary gland—Graves' disease	0.00071	0.0108	CbGeAlD
Doxorubicin—AKR1C3—adipose tissue—Graves' disease	0.000707	0.0107	CbGeAlD
Doxorubicin—Vertigo—Methimazole—Graves' disease	0.000683	0.0107	CcSEcCtD
Doxorubicin—Leukopenia—Methimazole—Graves' disease	0.000681	0.0106	CcSEcCtD
Doxorubicin—RALBP1—thyroid gland—Graves' disease	0.000664	0.0101	CbGeAlD
Doxorubicin—Alopecia—Propylthiouracil—Graves' disease	0.000656	0.0103	CcSEcCtD
Doxorubicin—NOS1—Serotonin Transporter Activity—IL1B—Graves' disease	0.000656	0.0328	CbGpPWpGaD
Doxorubicin—NOS3—thyroid gland—Graves' disease	0.000653	0.00993	CbGeAlD
Doxorubicin—POR—pituitary gland—Graves' disease	0.000648	0.00985	CbGeAlD
Doxorubicin—Myalgia—Methimazole—Graves' disease	0.000647	0.0101	CcSEcCtD
Doxorubicin—Arthralgia—Methimazole—Graves' disease	0.000647	0.0101	CcSEcCtD
Doxorubicin—POR—adipose tissue—Graves' disease	0.000646	0.00981	CbGeAlD
Doxorubicin—Dysgeusia—Propylthiouracil—Graves' disease	0.000633	0.0099	CcSEcCtD
Doxorubicin—Oedema—Methimazole—Graves' disease	0.000621	0.0097	CcSEcCtD
Doxorubicin—CBR1—thyroid gland—Graves' disease	0.00062	0.00942	CbGeAlD
Doxorubicin—AKR1C3—thyroid gland—Graves' disease	0.000612	0.0093	CbGeAlD
Doxorubicin—Thrombocytopenia—Methimazole—Graves' disease	0.000608	0.0095	CcSEcCtD
Doxorubicin—TOP2A—adipose tissue—Graves' disease	0.000602	0.00915	CbGeAlD
Doxorubicin—Vertigo—Propylthiouracil—Graves' disease	0.000581	0.00908	CcSEcCtD
Doxorubicin—Leukopenia—Propylthiouracil—Graves' disease	0.000579	0.00905	CcSEcCtD
Doxorubicin—NQO1—pituitary gland—Graves' disease	0.000576	0.00875	CbGeAlD
Doxorubicin—NQO1—adipose tissue—Graves' disease	0.000574	0.00872	CbGeAlD
Doxorubicin—Musculoskeletal discomfort—Methimazole—Graves' disease	0.000566	0.00884	CcSEcCtD
Doxorubicin—POR—thyroid gland—Graves' disease	0.000559	0.0085	CbGeAlD
Doxorubicin—Paraesthesia—Methimazole—Graves' disease	0.000557	0.00871	CcSEcCtD
Doxorubicin—Somnolence—Methimazole—Graves' disease	0.000552	0.00863	CcSEcCtD
Doxorubicin—Arthralgia—Propylthiouracil—Graves' disease	0.000551	0.00861	CcSEcCtD
Doxorubicin—Myalgia—Propylthiouracil—Graves' disease	0.000551	0.00861	CcSEcCtD
Doxorubicin—Dyspepsia—Methimazole—Graves' disease	0.000546	0.00854	CcSEcCtD
Doxorubicin—CYP1B1—eye—Graves' disease	0.000545	0.00828	CbGeAlD
Doxorubicin—Oedema—Propylthiouracil—Graves' disease	0.000528	0.00825	CcSEcCtD
Doxorubicin—CYP1B1—connective tissue—Graves' disease	0.000525	0.00798	CbGeAlD
Doxorubicin—TOP2A—thyroid gland—Graves' disease	0.000521	0.00792	CbGeAlD
Doxorubicin—Thrombocytopenia—Propylthiouracil—Graves' disease	0.000517	0.00808	CcSEcCtD
Doxorubicin—ABCC3—adipose tissue—Graves' disease	0.000515	0.00783	CbGeAlD
Doxorubicin—ABCC10—pituitary gland—Graves' disease	0.000514	0.00782	CbGeAlD
Doxorubicin—ABCC10—adipose tissue—Graves' disease	0.000512	0.00779	CbGeAlD
Doxorubicin—NQO1—thyroid gland—Graves' disease	0.000496	0.00755	CbGeAlD
Doxorubicin—Urticaria—Methimazole—Graves' disease	0.000493	0.00771	CcSEcCtD
Doxorubicin—Body temperature increased—Methimazole—Graves' disease	0.000491	0.00767	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.000481	0.00752	CcSEcCtD
Doxorubicin—Paraesthesia—Propylthiouracil—Graves' disease	0.000474	0.00741	CcSEcCtD
Doxorubicin—Somnolence—Propylthiouracil—Graves' disease	0.000469	0.00734	CcSEcCtD
Doxorubicin—Dyspepsia—Propylthiouracil—Graves' disease	0.000465	0.00726	CcSEcCtD
Doxorubicin—ABCC3—thyroid gland—Graves' disease	0.000446	0.00677	CbGeAlD
Doxorubicin—ABCC10—thyroid gland—Graves' disease	0.000443	0.00674	CbGeAlD
Doxorubicin—Pruritus—Methimazole—Graves' disease	0.000439	0.00687	CcSEcCtD
Doxorubicin—Urticaria—Propylthiouracil—Graves' disease	0.000419	0.00656	CcSEcCtD
Doxorubicin—Body temperature increased—Propylthiouracil—Graves' disease	0.000417	0.00652	CcSEcCtD
Doxorubicin—NOS2—Type II interferon signaling (IFNG)—CXCL10—Graves' disease	0.000417	0.0208	CbGpPWpGaD
Doxorubicin—CYP1B1—pituitary gland—Graves' disease	0.000404	0.00615	CbGeAlD
Doxorubicin—CYP1B1—adipose tissue—Graves' disease	0.000403	0.00612	CbGeAlD
Doxorubicin—Vomiting—Methimazole—Graves' disease	0.000395	0.00617	CcSEcCtD
Doxorubicin—Rash—Methimazole—Graves' disease	0.000391	0.00612	CcSEcCtD
Doxorubicin—Dermatitis—Methimazole—Graves' disease	0.000391	0.00611	CcSEcCtD
Doxorubicin—Headache—Methimazole—Graves' disease	0.000389	0.00608	CcSEcCtD
Doxorubicin—ABCB8—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000389	0.0194	CbGpPWpGaD
Doxorubicin—Pruritus—Propylthiouracil—Graves' disease	0.000373	0.00584	CcSEcCtD
Doxorubicin—Nausea—Methimazole—Graves' disease	0.000369	0.00576	CcSEcCtD
Doxorubicin—ABCC1—pituitary gland—Graves' disease	0.000364	0.00553	CbGeAlD
Doxorubicin—ABCC1—adipose tissue—Graves' disease	0.000362	0.00551	CbGeAlD
Doxorubicin—NDUFS2—p73 transcription factor network—FAS—Graves' disease	0.00036	0.0179	CbGpPWpGaD
Doxorubicin—CYP1B1—thyroid gland—Graves' disease	0.000349	0.0053	CbGeAlD
Doxorubicin—NOS2—Type II interferon signaling (IFNG)—HLA-B—Graves' disease	0.00034	0.017	CbGpPWpGaD
Doxorubicin—Vomiting—Propylthiouracil—Graves' disease	0.000336	0.00525	CcSEcCtD
Doxorubicin—Rash—Propylthiouracil—Graves' disease	0.000333	0.0052	CcSEcCtD
Doxorubicin—Dermatitis—Propylthiouracil—Graves' disease	0.000332	0.0052	CcSEcCtD
Doxorubicin—Headache—Propylthiouracil—Graves' disease	0.000331	0.00517	CcSEcCtD
Doxorubicin—ABCC1—thyroid gland—Graves' disease	0.000314	0.00477	CbGeAlD
Doxorubicin—Nausea—Propylthiouracil—Graves' disease	0.000313	0.0049	CcSEcCtD
Doxorubicin—ABCG2—pituitary gland—Graves' disease	0.000301	0.00458	CbGeAlD
Doxorubicin—ABCG2—adipose tissue—Graves' disease	0.0003	0.00456	CbGeAlD
Doxorubicin—NOS1—Monoamine Transport—IL1B—Graves' disease	0.000279	0.0139	CbGpPWpGaD
Doxorubicin—NOS2—Type II interferon signaling (IFNG)—ICAM1—Graves' disease	0.000276	0.0138	CbGpPWpGaD
Doxorubicin—ABCG2—thyroid gland—Graves' disease	0.00026	0.00395	CbGeAlD
Doxorubicin—YWHAG—FoxO family signaling—FASLG—Graves' disease	0.00026	0.013	CbGpPWpGaD
Doxorubicin—NOS2—IL12-mediated signaling events—CD8A—Graves' disease	0.00024	0.012	CbGpPWpGaD
Doxorubicin—SLC22A16—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00024	0.012	CbGpPWpGaD
Doxorubicin—NOS1—Alzheimers Disease—FAS—Graves' disease	0.000232	0.0116	CbGpPWpGaD
Doxorubicin—NOS2—IL12-mediated signaling events—FASLG—Graves' disease	0.000226	0.0113	CbGpPWpGaD
Doxorubicin—NQO1—Validated transcriptional targets of TAp63 isoforms—FAS—Graves' disease	0.000226	0.0113	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—CXCL10—Graves' disease	0.000219	0.0109	CbGpPWpGaD
Doxorubicin—NOS2—IL12-mediated signaling events—IL2RA—Graves' disease	0.000217	0.0108	CbGpPWpGaD
Doxorubicin—NOS2—IL12-mediated signaling events—HLA-A—Graves' disease	0.000214	0.0107	CbGpPWpGaD
Doxorubicin—NOS2—IL23-mediated signaling events—IFNG—Graves' disease	0.00021	0.0105	CbGpPWpGaD
Doxorubicin—NOS2—Type II interferon signaling (IFNG)—IFNG—Graves' disease	0.00021	0.0105	CbGpPWpGaD
Doxorubicin—NOS2—IL23-mediated signaling events—CD4—Graves' disease	0.000203	0.0101	CbGpPWpGaD
Doxorubicin—NOS1—Monoamine Transport—TNF—Graves' disease	0.000203	0.0101	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000202	0.0101	CbGpPWpGaD
Doxorubicin—NOS2—IL12-mediated signaling events—HLA-DRB1—Graves' disease	0.000196	0.00976	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000188	0.0094	CbGpPWpGaD
Doxorubicin—NOS2—IL23-mediated signaling events—IL1B—Graves' disease	0.000188	0.00936	CbGpPWpGaD
Doxorubicin—NOS2—Type II interferon signaling (IFNG)—IL1B—Graves' disease	0.000188	0.00936	CbGpPWpGaD
Doxorubicin—ABCC6—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000182	0.00909	CbGpPWpGaD
Doxorubicin—NOS1—Amyotrophic lateral sclerosis (ALS)—TNF—Graves' disease	0.000177	0.00882	CbGpPWpGaD
Doxorubicin—NOS3—SHP2 signaling—IL2RA—Graves' disease	0.000173	0.00862	CbGpPWpGaD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000168	0.0084	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—CXCL10—Graves' disease	0.000165	0.00823	CbGpPWpGaD
Doxorubicin—ABCC10—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000159	0.00794	CbGpPWpGaD
Doxorubicin—NOS3—Thromboxane A2 receptor signaling—ICAM1—Graves' disease	0.000154	0.00769	CbGpPWpGaD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.00015	0.00749	CbGpPWpGaD
Doxorubicin—ABCB1—pituitary gland—Graves' disease	0.000149	0.00226	CbGeAlD
Doxorubicin—ABCB1—adipose tissue—Graves' disease	0.000148	0.00225	CbGeAlD
Doxorubicin—NOS1—Spinal Cord Injury—ICAM1—Graves' disease	0.000145	0.00723	CbGpPWpGaD
Doxorubicin—NOS2—ATF-2 transcription factor network—IFNG—Graves' disease	0.000145	0.00723	CbGpPWpGaD
Doxorubicin—NOS2—IL12-mediated signaling events—IFNG—Graves' disease	0.000143	0.00713	CbGpPWpGaD
Doxorubicin—NOS2—IL12-mediated signaling events—CD4—Graves' disease	0.000138	0.00689	CbGpPWpGaD
Doxorubicin—NOS2—IL23-mediated signaling events—TNF—Graves' disease	0.000136	0.00679	CbGpPWpGaD
Doxorubicin—NOS1—Alzheimers Disease—IL1B—Graves' disease	0.000136	0.00677	CbGpPWpGaD
Doxorubicin—ABCB1—thyroid gland—Graves' disease	0.000128	0.00195	CbGeAlD
Doxorubicin—NOS2—IL12-mediated signaling events—IL1B—Graves' disease	0.000127	0.00636	CbGpPWpGaD
Doxorubicin—XDH—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000118	0.00589	CbGpPWpGaD
Doxorubicin—NOS3—SHP2 signaling—IFNG—Graves' disease	0.000114	0.00569	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—GC—Graves' disease	0.000113	0.00562	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—GC—Graves' disease	0.000113	0.00562	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—IFNG—Graves' disease	0.00011	0.0055	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—ICAM1—Graves' disease	0.000109	0.00546	CbGpPWpGaD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000109	0.00544	CbGpPWpGaD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	0.000109	0.00544	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000106	0.0053	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—GC—Graves' disease	0.000106	0.00528	CbGpPWpGaD
Doxorubicin—YWHAG—Apoptosis—FASLG—Graves' disease	0.000103	0.00516	CbGpPWpGaD
Doxorubicin—YWHAG—Apoptosis—FAS—Graves' disease	9.96e-05	0.00497	CbGpPWpGaD
Doxorubicin—NOS1—Alzheimers Disease—TNF—Graves' disease	9.84e-05	0.00491	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—IL1B—Graves' disease	9.83e-05	0.00491	CbGpPWpGaD
Doxorubicin—NQO1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—Graves' disease	9.73e-05	0.00485	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—GC—Graves' disease	8.99e-05	0.00449	CbGpPWpGaD
Doxorubicin—XDH—Selenium Micronutrient Network—IFNG—Graves' disease	8.98e-05	0.00448	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—B3GNT2—Graves' disease	8.53e-05	0.00426	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—B3GNT2—Graves' disease	8.53e-05	0.00426	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—GC—Graves' disease	8.39e-05	0.00419	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—IFNG—Graves' disease	8.32e-05	0.00415	CbGpPWpGaD
Doxorubicin—NOS3—Angiopoietin receptor Tie2-mediated signaling—TNF—Graves' disease	8.31e-05	0.00415	CbGpPWpGaD
Doxorubicin—NOS2—Circadian rythm related genes—FAS—Graves' disease	8.28e-05	0.00413	CbGpPWpGaD
Doxorubicin—NOS3—Leptin signaling pathway—IL1B—Graves' disease	8.28e-05	0.00413	CbGpPWpGaD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	8.09e-05	0.00404	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—B3GNT2—Graves' disease	8.02e-05	0.004	CbGpPWpGaD
Doxorubicin—XDH—Selenium Micronutrient Network—IL1B—Graves' disease	8.01e-05	0.004	CbGpPWpGaD
Doxorubicin—NOS1—Myometrial Relaxation and Contraction Pathways—IL1B—Graves' disease	7.91e-05	0.00395	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—IL1B—Graves' disease	7.42e-05	0.0037	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—GC—Graves' disease	7.27e-05	0.00363	CbGpPWpGaD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	7.21e-05	0.0036	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—TNF—Graves' disease	7.14e-05	0.00356	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—GC—Graves' disease	6.97e-05	0.00348	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—B3GNT2—Graves' disease	6.82e-05	0.0034	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—B3GNT2—Graves' disease	6.36e-05	0.00317	CbGpPWpGaD
Doxorubicin—NOS1—Disease—B3GNT2—Graves' disease	6.17e-05	0.00308	CbGpPWpGaD
Doxorubicin—ABCC3—Transmembrane transport of small molecules—GABRA3—Graves' disease	6.16e-05	0.00308	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	6.11e-05	0.00305	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	5.9e-05	0.00294	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—HLA-E—Graves' disease	5.86e-05	0.00292	CbGpPWpGaD
Doxorubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IL1B—Graves' disease	5.83e-05	0.00291	CbGpPWpGaD
Doxorubicin—XDH—Selenium Micronutrient Network—TNF—Graves' disease	5.81e-05	0.0029	CbGpPWpGaD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—IL1B—Graves' disease	5.8e-05	0.00289	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—CD40—Graves' disease	5.73e-05	0.00286	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—FAS—Graves' disease	5.66e-05	0.00283	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—CTLA4—Graves' disease	5.64e-05	0.00282	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—GC—Graves' disease	5.46e-05	0.00273	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—TNF—Graves' disease	5.38e-05	0.00269	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—GC—Graves' disease	5.28e-05	0.00264	CbGpPWpGaD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	5.23e-05	0.00261	CbGpPWpGaD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor—TNF—Graves' disease	5.23e-05	0.00261	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—IL2RA—Graves' disease	5.21e-05	0.0026	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—GC—Graves' disease	4.9e-05	0.00244	CbGpPWpGaD
Doxorubicin—ABCC2—Transmembrane transport of small molecules—GABRA3—Graves' disease	4.89e-05	0.00244	CbGpPWpGaD
Doxorubicin—ABCC1—Transmembrane transport of small molecules—GABRA3—Graves' disease	4.83e-05	0.00241	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—GC—Graves' disease	4.73e-05	0.00236	CbGpPWpGaD
Doxorubicin—NOS2—Disease—B3GNT2—Graves' disease	4.65e-05	0.00232	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	4.65e-05	0.00232	CbGpPWpGaD
Doxorubicin—NOS3—Myometrial Relaxation and Contraction Pathways—IL1B—Graves' disease	4.63e-05	0.00231	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TSHR—Graves' disease	4.48e-05	0.00223	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—GC—Graves' disease	4.39e-05	0.00219	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—B3GNT2—Graves' disease	4.28e-05	0.00213	CbGpPWpGaD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—GABRA3—Graves' disease	4.25e-05	0.00212	CbGpPWpGaD
Doxorubicin—YWHAG—Apoptosis—TNF—Graves' disease	4.23e-05	0.00211	CbGpPWpGaD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—TNF—Graves' disease	4.21e-05	0.0021	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—HLA-B—Graves' disease	4.17e-05	0.00208	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—FASLG—Graves' disease	4.08e-05	0.00204	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—GC—Graves' disease	3.99e-05	0.00199	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—FAS—Graves' disease	3.93e-05	0.00196	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—IL2RA—Graves' disease	3.93e-05	0.00196	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IL2RA—Graves' disease	3.91e-05	0.00195	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—HLA-A—Graves' disease	3.87e-05	0.00193	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—B3GNT2—Graves' disease	3.71e-05	0.00185	CbGpPWpGaD
Doxorubicin—NOS3—Disease—B3GNT2—Graves' disease	3.61e-05	0.0018	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—B3GNT2—Graves' disease	3.58e-05	0.00179	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	3.53e-05	0.00176	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—B3GNT2—Graves' disease	3.33e-05	0.00166	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—GC—Graves' disease	3.24e-05	0.00162	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—GC—Graves' disease	3.1e-05	0.00155	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—IL2RA—Graves' disease	3.05e-05	0.00152	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—B3GNT2—Graves' disease	3.03e-05	0.00151	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CXCL10—Graves' disease	2.89e-05	0.00144	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IFNG—Graves' disease	2.58e-05	0.00129	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	2.5e-05	0.00125	CbGpPWpGaD
Doxorubicin—NOS1—Disease—HLA-A—Graves' disease	2.5e-05	0.00125	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TSHR—Graves' disease	2.48e-05	0.00124	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—B3GNT2—Graves' disease	2.45e-05	0.00123	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GC—Graves' disease	2.43e-05	0.00121	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GC—Graves' disease	2.35e-05	0.00117	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—B3GNT2—Graves' disease	2.35e-05	0.00117	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IL1B—Graves' disease	2.3e-05	0.00115	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	2.3e-05	0.00115	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IL2RA—Graves' disease	2.21e-05	0.0011	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—B3GNT2—Graves' disease	2.2e-05	0.0011	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GC—Graves' disease	2.14e-05	0.00107	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TSHR—Graves' disease	2.1e-05	0.00105	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	2.01e-05	0.001	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	1.94e-05	0.000969	CbGpPWpGaD
Doxorubicin—NOS2—Disease—HLA-A—Graves' disease	1.88e-05	0.00094	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—B3GNT2—Graves' disease	1.84e-05	0.00092	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—B3GNT2—Graves' disease	1.78e-05	0.00089	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—HLA-A—Graves' disease	1.73e-05	0.000864	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—TNF—Graves' disease	1.67e-05	0.000834	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—B3GNT2—Graves' disease	1.62e-05	0.00081	CbGpPWpGaD
Doxorubicin—NOS1—Disease—CD4—Graves' disease	1.61e-05	0.000803	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CXCL10—Graves' disease	1.6e-05	0.0008	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GC—Graves' disease	1.57e-05	0.000783	CbGpPWpGaD
Doxorubicin—NOS3—Disease—HLA-A—Graves' disease	1.46e-05	0.00073	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CXCL10—Graves' disease	1.35e-05	0.000676	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL2RA—Graves' disease	1.23e-05	0.000612	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CD4—Graves' disease	1.21e-05	0.000606	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—B3GNT2—Graves' disease	1.19e-05	0.000594	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GC—Graves' disease	1.16e-05	0.000578	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CD4—Graves' disease	1.11e-05	0.000557	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GC—Graves' disease	1.09e-05	0.000544	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL2RA—Graves' disease	1.04e-05	0.000517	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CD4—Graves' disease	9.42e-06	0.00047	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HLA-A—Graves' disease	8.91e-06	0.000445	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—B3GNT2—Graves' disease	8.77e-06	0.000438	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—B3GNT2—Graves' disease	8.27e-06	0.000413	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	8.24e-06	0.000411	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GC—Graves' disease	7.13e-06	0.000356	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CD4—Graves' disease	5.74e-06	0.000287	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—B3GNT2—Graves' disease	5.4e-06	0.00027	CbGpPWpGaD
